Provided by Tiger Fintech (Singapore) Pte. Ltd.

SIMPLIFY CHINA A SHARES PLUS INCOME ETF

25.55
+0.0000
Volume:298.00
Turnover:7.84K
Market Cap:734.42M
PE:- -
High:25.55
Open:25.55
Low:25.55
Close:25.55
Loading ...

IBM vs. Microsoft: Which Cloud Computing Stock is a Better Bet?

Zacks
·
16 Apr

Newmont vs. Barrick Gold: Which Mining Giant Is the Better Bet Now?

Zacks
·
07 Apr

IBM Soars 32% in the Past Year: Should the Stock Be in Your Portfolio?

Zacks
·
01 Apr

L3Harris Technologies Closes Sale of CAS Business for $800 Million

MT Newswires Live
·
31 Mar

Newmont Gains 28% YTD: How Should Investors Play the Stock?

Zacks
·
21 Mar

IBM Extends NVIDIA Collaboration for AI Scalability: Stock to Gain?

Zacks
·
19 Mar

IBM Taps NVIDIA AI Data Platform Technologies to Accelerate AI at Scale

PR Newswire
·
19 Mar

Garmin G3000 PRIME unveiled as integrated flight deck for the new Pilatus PC-12 PRO aircraft

PR Newswire
·
17 Mar

Amex Halt Add Info Lst 22.550000

THOMSON REUTERS
·
05 Mar

Distributor Purchasing Shifts Mar MDT's Q3 Show: How to Play the Stock

Zacks
·
25 Feb

Is this America’s first electric refrigerated catering truck for aviation?

Electrek
·
09 Feb

L3Harris Technologies Reports Fourth Quarter and Full-Year 2024 Results, Initiates 2025 Guidance

Business Wire
·
30 Jan

RTX Reports 2024 Results and Announces 2025 Outlook

PR Newswire
·
28 Jan

Boeing Reports Fourth Quarter Results

PR Newswire
·
28 Jan

Verimatrix Announces Release of DVB ReAccess Over-the-Air CAS Retrofit Solution

Business Wire
·
15 Jan

Newmont Stock Loses 27% in 3 Months: Should You Buy Now?

Zacks
·
09 Jan

Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease

Business Wire
·
08 Jan

ACELYRIN, INC. Announces Additional Phase 2 Data and Phase 3 Program Design for Lonigutamab in Thyroid Eye Disease

GlobeNewswire
·
07 Jan

Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease

Business Wire
·
16 Dec 2024

NSPR Stock May Gain as First Patient Enrolls in CGUARDIANS II Study

Zacks
·
12 Dec 2024